{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.8","upperLimit":"29.3","value":"15"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"14.8","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Proportion of subjects with the best overall response of complete response (CR) or partial response (PR).","dispersionType":"99% Confidence Interval","groups":[{"description":"cabozantinib (60 mg) once daily orally (qd)\n\nCabozantinib: Tablets containing 60-mg or 20-mg cabozantinib once daily orally.","id":"OG000","title":"Cabozantinib"},{"description":"placebo once daily orally (qd)\n\nPlacebo: Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The first 100 subjects randomized.","reportingStatus":"POSTED","timeFrame":"Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}